Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4236MR)

This product GTTS-WQ4236MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4236MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ285MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ8275MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ14387MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ916MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ6632MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ880MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ5403MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ5451MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW